Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Event Calendar
Subscribe

|Articles|April 15, 2016

Episode 2: How On-Dose Technologies Mitigate Safety Risks and Reduce Product Diversion and Counterfeiting

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Stock.adobe.com

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons

July 21st 2026

stock.Adobe.com

Pharmaceutical Executive Daily: FDA Grants Emergency Use Authorization to Allplex Assay

ByNicholas Jacobus

July 21st 2026

stock.adobe.com DNA strand

FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay

ByNicholas Jacobus

July 21st 2026

Gurinder S. Sidhu, M.D.

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

ByNicholas Jacobus,Gurinder S. Sidhu, MD

July 21st 2026

David Hung

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

ByMike Hollan,David Hung

July 21st 2026

Trending on PharmExec

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay